Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$121.46K$121.46Kderived+38,337.7% vs Q4 2021 Net Income-$12.93M-$12.93MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$116,597N/M Operating Incomederived-$483,051N/M Operating Cash Flowderived-$225,541N/M Margins · derivedGross margin96.0%+2800.1 pt vs Q4 2021
Operating margin-397.7%+117891.5 pt vs Q4 2021
Net margin-10647.0%
ended Dec 31, 2022 · filed Apr 17, 2023 · 107 d after period end